Search Results 1951-1960 of 19639 for hemoglobin

1. Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer - Mayo Clinic

   Hemoglobin >= 9 g/dL; Thyroid stimulating hormone (TSH) < lower limit of normal (LLN) (patients not able to tolerate TSH suppression can be granted an ...

2. VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer - Mayo Clinic

   Hemoglobin > 9 g/dL, transfusion permitted; Total bilirubin < 1.5 x upper limit of normal (ULN) (or < 3 x ULN for subjects with Gilbert's syndrome) ...

3. A Study to Determine Recommended Dose, Regimen and Evaluate the Safety and Preliminary Effectiveness of CC-92480 in Combination With Standard Treatments in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) - Mayo Clinic

   Hemoglobin < 8 g/dL (< 4.9 mmol/L);; Creatinine clearance (CrCl) < 45 mL/min (< 30 mL/min for Cohort G);; Corrected serum calcium > 13.5 mg/dL (> 3.4 mmol/L); ...

4. A Study to Assess the Safety and Dose Escalation of Pegtomarginase (PT01) for Subjects with Advanced Malignancies - Mayo Clinic

   Hemoglobin ≥ 90 g/L. Adequate liver function as demonstrated by: Serum bilirubin < 2 × the upper limit of normal (ULN);; Aspartate transaminase (AST) and ...

5. Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study - Mayo Clinic

   * Hemoglobin \>= 8.0 g/dL (obtained =\< 14 days prior to registration) * Absolute neutrophil count (ANC) \>= 1000/mm\^3 (obtained =\< 14 days prior to ...

6. PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy - Mayo Clinic

   - Hemoglobin > 11 g/dL - NOTE: Patients with a history of metastatic breast cancer or an ECOG performance status of 2 must have this lab completed =< 28 ...

7. Efficacy, Safety, And Tolerability Study Of Lunsekimig Compared With Placebo In Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized By An Eosinophilic Phenotype PERSEPHONE - Mayo Clinic

   Hemoglobin <10 g/100 mL for male and <9 g/100 mL for female. Neutrophils <1500/μL (<1000/μL for those of African descent). Platelets <100 000/μL. Creatinine ...

8. A Study of Taxane, Trastuzumab, and Pertuzumab With or Without Atezolizumab in Treating Metastatic Breast Cancer Patients - Mayo Clinic

   Hemoglobin must be ≥ 8 g/dL (within 14 days prior to randomization). Total bilirubin must be ≤ 1.5 x upper limit of normal (ULN) for the lab or direct ...

9. A Study of TAK-981 in Combination with Rituximab in Participants with Relapsed/Refractory (r/r) CD20-positive (CD20+) Non-Hodgkin Lymphoma (NHL) - Mayo Clinic

   Hemoglobin ≥ 85 gram per liter (g/L) (red blood cell [RBC] transfusion allowed ≥ 14 days before assessment). Adequate renal and hepatic function, per ...

10. Study Evaluating the Safety and Effectiveness of JCARH125 in Subjects with Relapsed and/or Refractory Multiple Myeloma (EVOLVE) - Mayo Clinic

    Adequate bone marrow function, defined as absolute neutrophil count (ANC) ≥ 1000 cells/mm3 , hemoglobin (Hb) ≥ 8 g/dL, and platelet count ≥ 50,000/mm^3.